Let us help you customize your experience.
Tell us a little about yourself so we can share more relevant content and resources.
This study will look at a new dry powder to be mixed with water before oral administration.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.